Transaction in Own Shares
CVS bought 134,615 ordinary shares between 26/10/2026 and 30/10/2026 at a volume-weighted average price of 1,317.86p (range 1,289.00p–1,339.00p) under its 26 May 2026 buyback and will cancel them; after cancellation CVS will have 66,695,634 shares in issue and no treasury shares. Since the programme commenced CVS has repurchased 3,467,465 shares at a weighted average price of 1,250.8p, equivalent to approximately 4.94% of the pre-programme share capital, which reduces the share base and total voting rights and is likely to be accretive to EPS per share.
Select text to share a quote on X · sign in to keep highlights & notes in your CVSG notes
CVS announces that it purchased the following number of its ordinary shares of 0.2 pence each (“Ordinary Shares”) from Joh. Berenberg, Gossler & Co. KG, London Branch (”Berenberg”), in accordance with the terms of the share buyback programme announced on 26 May 2026 (the "Share Buyback Programme").
| Date of purchases: | 26/10/2026 – 30/10/2026 |
|---|---|
| Aggregate number of Ordinary Shares purchased: | 134,615 |
| Lowest price paid per share (GBp): | 1,289.00 |
| Highest price paid per share (GBp): | 1,339.00 |
| Volume weighted average price paid per share (GBp): | 1,317.86 |
CVS intends to cancel all of the purchased Ordinary Shares.
Following settlement of the above purchases and cancellation of the Ordinary Shares purchased, CVS will have 66,695,634 Ordinary Shares in issue and holds no Ordinary Shares in treasury.
The total number of voting rights in CVS is therefore 66,695,634 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, CVS under the Financial Conduct Authority's Disclosure and Transparency Rules.
Since the commencement of the Share Buyback Programme, the Company has repurchased 3,467,465 Ordinary Shares in aggregate at a weighted average price of 1,250.8 pence per share.
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), as it forms part of Retained EU Law as defined in the European Union (Withdrawal) Act 2018, (a full breakdown of the individual trades made by Berenberg as part of the Share Buyback Programme is attached to this announcement).
| Contacts CVS Group plc Richard Fairman, Chief Executive Officer Robin Alfonso, Chief Financial Officer Paul Higgs, Chief Veterinary Officer Charlotte Page, Head of Investor Relations | via FGS Global |
| FGS Global Faeth Birch Charlie Chichester | +44 (0)207 251 3801 cvsgroup@fgsglobal.com |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.